206A — PRISM Biolab Co Income Statement
0.000.00%
Last trade - 00:00- ¥7bn
- ¥4bn
- ¥677m
Annual income statement for PRISM Biolab Co, fiscal year end - September 30th, JPY millions except per share, conversion factor applied.
2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho |
| Standards: | — | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 554 | 113 | 306 | 677 |
| Cost of Revenue | ||||
| Gross Profit | 535 | 80.3 | 161 | 270 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 492 | 638 | 1,305 | 1,535 |
| Operating Profit | 62.2 | -525 | -999 | -857 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 74.2 | -526 | -1,048 | -831 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 73 | -527 | -1,050 | -834 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 73 | -527 | -1,050 | -834 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 73 | -527 | -1,050 | -834 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 2.19 | -14.4 | -25.3 | -21.3 |
| Dividends per Share |